Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for KRYS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 1.359B
March 31, 2026 1.277B
December 31, 2025 1.220B
September 30, 2025 1.138B
June 30, 2025 1.041B
March 31, 2025 984.67M
December 31, 2024 946.38M
September 30, 2024 885.85M
June 30, 2024 838.89M
March 31, 2024 799.24M
December 31, 2023 778.64M
September 30, 2023 755.95M
June 30, 2023 653.11M
March 31, 2023 489.57M
December 31, 2022 522.23M
September 30, 2022 540.77M
June 30, 2022 559.18M
March 31, 2022 548.55M
December 31, 2021 593.58M
September 30, 2021 408.24M
Date Value
June 30, 2021 418.54M
March 31, 2021 430.65M
December 31, 2020 292.08M
September 30, 2020 301.72M
June 30, 2020 309.70M
March 31, 2020 198.37M
December 31, 2019 202.91M
September 30, 2019 207.65M
June 30, 2019 198.29M
March 31, 2019 109.49M
December 31, 2018 113.23M
September 30, 2018 52.29M
June 30, 2018 45.27M
March 31, 2018 47.40M
December 31, 2017 49.47M
September 30, 2017 50.20M
June 30, 2017 -0.829M
March 31, 2017 -0.114M
December 31, 2016 0.289M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Marker Therapeutics, Inc. 12.17M
TG Therapeutics, Inc. 604.08M
Tenaya Therapeutics, Inc. 69.41M
Cytokinetics, Inc. -173.49M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics